Cargando…

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

Renal cell carcinoma encompass distinct diseases with different pathologic features and distinct molecular pathways. Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway alone or in combination have greatly changed clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kammerer-Jacquet, Solène-Florence, Deleuze, Antoine, Saout, Judikaël, Mathieu, Romain, Laguerre, Brigitte, Verhoest, Gregory, Dugay, Frédéric, Belaud-Rotureau, Marc-Antoine, Bensalah, Karim, Rioux-Leclercq, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480014/ https://www.ncbi.nlm.nih.gov/pubmed/30987368 http://dx.doi.org/10.3390/ijms20071692

Ejemplares similares

Immunotherapy in Renal Cell Carcinoma: The Future Is Now
por: Deleuze, Antoine, et al.
Publicado: (2020)

Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma
por: Verhoest, Grégory, et al.
Publicado: (2014)

Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models
por: Ouzaid, Idir, et al.
Publicado: (2022)

Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients
por: Ouzaid, Idir, et al.
Publicado: (2020)

Transperitoneal Laparoscopic Nephrectomy for Autosomal Dominant Polycystic Kidney Disease
por: Verhoest, Grégory, et al.
Publicado: (2012)

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
por: Dugay, Frédéric, et al.
Publicado: (2017)

Deep Learning Methodologies Applied to Digital Pathology in Prostate Cancer: A Systematic Review
por: Rabilloud, Noémie, et al.
Publicado: (2023)

Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma
por: Khene, Zine-Eddine, et al.
Publicado: (2016)

Whole genome duplication is an early event leading to aneuploidy in IDH-wild type glioblastoma
por: Boisselier, Blandine, et al.
Publicado: (2018)

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
por: Parker, David, et al.
Publicado: (2014)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?
por: Dolley-Hitze, T, et al.
Publicado: (2010)

Artificial Intelligence-Based Opportunities in Liver Pathology—A Systematic Review
por: Allaume, Pierre, et al.
Publicado: (2023)

Array-CGH diagnosis in ovarian failure: identification of new molecular actors for ovarian physiology
por: Jaillard, Sylvie, et al.
Publicado: (2016)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

PD-1/PD-L1 binding studies using microscale thermophoresis
por: Magnez, Romain, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L1 expression in anal squamous intraepithelial lesions
por: Bucau, Margot, et al.
Publicado: (2020)

Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study
por: Favaretto, Ricardo L., et al.
Publicado: (2016)

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
por: Dousset, Léa, et al.
Publicado: (2021)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients
por: Hagedorn, Martin, et al.
Publicado: (2007)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
por: Larroquette, Mathieu, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dc5jb310arl5jjlk1k3aptddik